We are a German company dedicated to researching, synthesizing and developing chemical compounds for the treatment of various ailments through novel study pathways.
Our main efforts are currently focused in the development of a novel peptide-based compound for the treatment of Alzheimer's Disease.
This peptide compound has proven effectiveness in animal models in not only preventing, but also reversing the cognitive impairment effects of Alzheimer's Disease. We are convinced this compound could become a major solution for the global challenge of treating dementia and memory loss.
Our team's international nature, multi-disciplinary expertise and passion, merge to create a group of professionals convinced of their capabilities to develop a solution for some of world's most important ailments.
Company Details
- Founded
- -
- Address
- München, Munich,bavaria,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.memosynepharma.com/
- Keywords
- Research & Development, Biotechnology, Compounds Development, Peptide Development, Treatments & Therapy, Chemical Compounds, Alzheimer's Disease, Investigation, Dementia, Alzheimer, Alzheimer Disease, Peptide Compounds.
- HQ
- Munich, Bavaria
Memosyne Questions
Memosyne's website is https://www.memosynepharma.com/
Memosyne's LinkedIn profile is https://de.linkedin.com/company/memosyne
Memosyne's industry is
Biotechnology Research
Memosyne's categories are Biotechnology Research
Memosyne's founding year is 2017
